Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancers.
about
Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximabIs there a role for epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor wild-type non-small cell lung cancer?EGFR ligands exhibit functional differences in models of paracrine and autocrine signalingAt the crossroads: EGFR and PTHrP signaling in cancer-mediated diseases of boneCharacterizing tyrosine phosphorylation signaling in lung cancer using SH2 profilingNovel mutant-selective EGFR kinase inhibitors against EGFR T790MA novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors.Colon cancer-derived oncogenic EGFR G724S mutant identified by whole genome sequence analysis is dependent on asymmetric dimerization and sensitive to cetuximab.Epidermal growth factor is a potential biomarker for poor cetuximab response in tongue cancer cells.Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma.Integrated genomic analysis of colorectal cancer progression reveals activation of EGFR through demethylation of the EREG promoterHER kinase axis receptor dimer partner switching occurs in response to EGFR tyrosine kinase inhibition despite failure to block cellular proliferationClinical utility of erlotinib for the treatment of non-small-cell lung cancer in Japanese patients: current evidenceWidespread potential for growth-factor-driven resistance to anticancer kinase inhibitors.Frequent deregulations in the hedgehog signaling network and cross-talks with the epidermal growth factor receptor pathway involved in cancer progression and targeted therapies.Analysis of growth factor signaling in genetically diverse breast cancer linesHedgehog signaling drives radioresistance and stroma-driven tumor repopulation in head and neck squamous cancers.Detection of the epidermal growth factor receptor, amphiregulin and epiregulin in formalin-fixed paraffin-embedded human placenta tissue by matrix-assisted laser desorption/ionization mass spectrometry imaging.The anti-HER3 antibody patritumab abrogates cetuximab resistance mediated by heregulin in colorectal cancer cellsSmall molecule inhibitors of the host cell COX/AREG/EGFR/ERK pathway attenuate cytomegalovirus-induced pathogenesisA stable IgG-like bispecific antibody targeting the epidermal growth factor receptor and the type I insulin-like growth factor receptor demonstrates superior anti-tumor activityXPF expression correlates with clinical outcome in squamous cell carcinoma of the head and neck.Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitorsTumor epidermal growth factor receptor genotype and depression in stage IV non-small cell lung cancer.Combined Analysis of Plasma Amphiregulin and Heregulin Predicts Response to Cetuximab in Metastatic Colorectal Cancer.HER family receptor abnormalities in lung cancer brain metastases and corresponding primary tumorsCetuximab and biomarkers in non-small-cell lung carcinomaTargeting autocrine HB-EGF signaling with specific ADAM12 inhibition using recombinant ADAM12 prodomain.Multimodality Approaches to Treat Hypoxic Non-Small Cell Lung Cancer (NSCLC) MicroenvironmentThe pan-HER family tyrosine kinase inhibitor afatinib overcomes HER3 ligand heregulin-mediated resistance to EGFR inhibitors in non-small cell lung cancerThe molecular pathogenesis of head and neck squamous cell carcinomaCytomegalovirus-induced salivary gland pathology: resistance to kinase inhibitors of the upregulated host cell EGFR/ERK pathway is associated with CMV-dependent stromal overexpression of IL-6 and fibronectinHedgehog signaling alters reliance on EGF receptor signaling and mediates anti-EGFR therapeutic resistance in head and neck cancerERRα mediates metabolic adaptations driving lapatinib resistance in breast cancerMAPK1E322K mutation increases head and neck squamous cell carcinoma sensitivity to erlotinib through enhanced secretion of amphiregulin.Pathogenesis of lung cancer signalling pathways: roadmap for therapies.Targeting EGFR resistance networks in head and neck cancer.Honokiol suppresses lung tumorigenesis by targeting EGFR and its downstream effectors.Heregulin-expressing HER2-positive breast and gastric cancer exhibited heterogeneous susceptibility to the anti-HER2 agents lapatinib, trastuzumab and T-DM1.JAK1/STAT3 activation through a proinflammatory cytokine pathway leads to resistance to molecularly targeted therapy in non-small cell lung cancer.
P2860
Q24600031-F3032597-8DA4-42B2-87FB-6D9868B2AB18Q26798882-4CD79555-2321-430D-BF87-3741E896F068Q26864769-C5792DAD-C791-4FDC-91FA-90F73EBBB68FQ26866067-E06C5BCC-A268-4709-B35A-B84F8B3677AFQ27317429-BA0BC998-FDED-4CB3-A5A7-F59B3D450870Q27658766-102CD11E-79A7-4033-8898-1D913D44C3F5Q27851660-6976697B-56DB-4CBD-A907-4B07B2310521Q27853014-B0C3290A-BE43-4E8E-82F1-18836A49851CQ27853131-A7203C32-D88C-4B9A-B9A2-7DF950CC1EFCQ27853189-C40DFA16-4FB6-4E0D-A769-D47CFD368AC7Q30276647-C5E78903-7E74-4668-81A7-F17979ED3088Q33699007-C4283710-6875-48F0-B5D2-58B0442828E8Q34011705-AD073FAB-57EB-4F40-B9BC-6272E05A60D8Q34032640-45635F12-51FA-4799-9582-66BC27E6915BQ34244929-62DFDF7C-67CF-4FF7-A02A-3601458C0919Q34522964-9264735F-3A0F-48C3-8731-D1B9315ED99CQ34620099-AB676648-57FF-4B2F-AF32-7B9AE0E558B3Q34809415-E931D434-7881-4D59-A7DF-0BA30ADBDA3EQ35068059-2E92531E-F003-4444-B6AF-4EC84B84D97CQ35115725-F4B341AF-F4C8-4FCB-B3FE-85BBD0D3A3E8Q35146077-191AD817-0144-4369-89A3-AE1AE60F61BAQ35167019-C8257519-877B-4DEE-97E0-559A81C1E675Q35212644-0CB7D87D-9286-492D-9207-FDB8D13BF534Q35584773-4FA0CC30-7410-4ADA-A867-62ED906EDCD6Q35841734-53577454-2205-4F34-B871-6E3931563087Q36025680-52B2AECA-6656-4453-B76A-E90F006936D0Q36171281-898CEF8D-4FD3-4FD7-8422-14038C835A8CQ36174467-A9E92F34-AC07-416F-9372-1DCA5C0FB4C6Q36296469-5ADC9FBF-BEBC-4DA1-A5FC-7846C1EEE4D9Q36545226-0BBD235D-B53C-4165-9878-94B0709D6786Q36659339-C0BBBD94-A771-43A5-A302-EECF874101E9Q36698067-BBA98D66-DECC-41EC-ACF7-FE3F5556BC96Q36906346-8EF98B2D-2935-4006-8844-F2E8A6E8AEC8Q37096669-BA8248BA-03D2-4492-9A60-D64D807EC9EEQ37268998-C567258D-247A-451E-BFCB-F23E9F7912F9Q37389526-2E8E8C8D-CF2B-42CD-835D-C083EAB36BF3Q37405633-A1826C53-04BE-4B92-83E2-6724F7C0D113Q37628928-8DE404DD-E13B-475D-9139-C2F16194E9CAQ37709032-22CF32E9-E42F-4789-9542-0A57DEBE7AB7Q38669181-1FC3DD0E-B79F-473C-B125-4F91688C3EC3
P2860
Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancers.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Autocrine production of amphir ...... mab in EGFR wild-type cancers.
@ast
Autocrine production of amphir ...... mab in EGFR wild-type cancers.
@en
type
label
Autocrine production of amphir ...... mab in EGFR wild-type cancers.
@ast
Autocrine production of amphir ...... mab in EGFR wild-type cancers.
@en
prefLabel
Autocrine production of amphir ...... mab in EGFR wild-type cancers.
@ast
Autocrine production of amphir ...... mab in EGFR wild-type cancers.
@en
P2093
P2860
P1476
Autocrine production of amphir ...... mab in EGFR wild-type cancers.
@en
P2093
Alison J Homes
Andrew M Rogers
Bruce E Johnson
David M Jackman
Kimio Yonesaka
Kreshnik Zejnullahu
Neal Lindeman
P2860
P304
P356
10.1158/1078-0432.CCR-08-0957
P407
P50
P577
2008-11-01T00:00:00Z